-
The clinical application of class 3.1 hepatitis C drug sofibvir of Kelun Pharmaceutical Co., Ltd. was accepted
Time of Update: 2014-11-17
The drug is regarded as a breakthrough drug for the treatment of hepatitis C, and the product was approved for marketing at the end of 2013, with sales revenue of US $8.67 billion as of the third quar
-
Take stock of patent applications of traditional Chinese medicine enterprises in October 2014
Time of Update: 2014-11-16
1 Total patent amount and ranking announced to key Chinese medicine enterprises in October [note] There are 46 patents for invention disclosure, utility model, design and invention authorization in th
-
Baiji Shenzhou completed the financing of 450 million yuan for three phase I clinical trials of anticancer drugs
Time of Update: 2014-11-15
This round of funds comes from the original angel and strategic investors as well as new investors: Hillhouse capital, the US dollar fund of CITIC Industrial Fund and a blue chip public investment fun
-
The Dilemma of Drug Approval: From "Great Leap Forward" to "Great Traffic Congestion"
Time of Update: 2014-11-15
In the practical context, drug evaluation is a highly professional work, but it is intertwined between the local economy, enterprise development and the vast number of patients and various gray intere
-
CDE first innovative drug approval "privilege" upon completion of phase II clinical approval
Time of Update: 2014-11-14
"Privilege" of approval of innovative drugs In 2009, China promulgated and implemented the regulations on the administration of special examination and approval of new drug registration According to t
-
Shunhao biological "preclinical and clinical research of endometrial regenerative cells in the treatment of premature ovarian failure" was supported by the national major new drug development project
Time of Update: 2014-11-14
On the morning of September 2, Gao Chang, vice president of Shunhao Cell Biotechnology (Tianjin) Co., Ltd., led the "national major science and technology project 2014" The team of "new drug creation"
-
Pidomode oral solution, a 6-class generic drug of Dikang Pharmaceutical Co., Ltd., will soon be approved for production
Time of Update: 2014-11-13
Dikang pharmaceutical insiders confirmed that the product company plans to serve as a processing agent, not as a key product Pidomode oral solution is an immunomodulator, which is suitable for patient
-
The first cross strait biotechnology and new drug industry cooperation forum was held in Taipei
Time of Update: 2014-11-12
The forum was jointly held by China pharmaceutical innovation promotion association and Taiwan biotechnology and medical industry promotion association The two sides signed a memorandum of cooperation
-
Dp-vpa, a new drug jointly developed by Enhua pharmaceutical and Israel, is in clinical research stage
Time of Update: 2014-11-12
At the same time, echakalin has entered the stage of production review According to the public information, the preventive and therapeutic effects of etacalin and its derivatives on pulmonary hyperten
-
Zhang Boli: research and development of new drugs in line with Chinese industrial characteristics
Time of Update: 2014-11-12
Zhang Boli, academician of Chinese Academy of engineering and President of Tianjin University of traditional Chinese medicine, made a keynote speech entitled "progress and trend of new drug research a
-
Two new drugs declared by Huahai pharmaceutical and Huabei pharmaceutical failed to pass the examination
Time of Update: 2014-11-12
The Policresulen Gel of arihua and Huarun of Shuanghua pharmaceutical company entered the approval process It is understood that aripiprazole is a kind of drug for the treatment of schizophrenia, whic
-
Class 1.1 new drugs declared for clinical use in 2014 (as of October)
Time of Update: 2014-11-11
It involves 50 enterprises or institutions - 46 enterprises and 4 research institutions Most enterprises or institutions have declared one variety (one API and one preparation in total), and only six
-
Inventory of Chinese generic drugs opening the door of FDA
Time of Update: 2014-11-11
Many pharmaceutical companies in China claim that their products have passed the FDA certification, but some of them are only APIs, some of them have not been approved in the end although they have ap
-
Adfovir dipivoxil tablets, a new hepatitis B drug of Guangji pharmaceutical industry, will soon be approved for production
Time of Update: 2014-11-11
On November 8, the progress of drug registration showed that the drug handling status of acceptance No "cxhs0700445 e" was changed to "certificate preparation completed - approved document" "The varie
-
Wuxi apptec: do not be a pharmaceutical enterprise, only provide R & D services for pharmaceutical enterprises
Time of Update: 2014-11-11
If we think of new drug research and development as a kitchen, pharmaceutical companies are like chefs Pharmaceutical R & D outsourcing service (CRO) company, Wuxi apptec new drug development Co., Ltd
-
"13th five year plan" for new drug development is about to emerge
Time of Update: 2014-11-07
The new concrete reporter of new drug research and development learned from the meeting that from 2008 to 2014, there were 1501 projects for major new drug creation and development, and the central fi
-
Preparation of lisinopril hydrochlorothiazide tablets
Time of Update: 2014-11-07
Huahai pharmaceutical company said that it was not sure whether the products were approved If approved, a notice would be issued According to the public data, lisinopril hydrochlorothiazide tablet is
-
Hengrui anti-tumor drug cyclophosphamide injection is approved to be listed in the United States
Time of Update: 2014-11-06
It is worth mentioning that only Baite International Co., Ltd in the United States has the injection approval before, and Hengrui pharmaceutical products have a large market space after being listed A
-
Antibiotic leading North China Pharmaceutical accelerates the first imitation and creation
Time of Update: 2014-11-05
Systemic antibacterials are necessary for the treatment of infectious diseases in clinic, which have the characteristics of wide clinical application and wide variety According to the report "antibact
-
Qilu pharmaceutical Shenjie leads the innovation of nerve repair drugs
Time of Update: 2014-11-05
Central nervous system injury is a common disease leading to human death and the main cause of human disability Every year, millions of new patients with central injury need to be treated in China, an
